



# noviocyte

the solution in 3D cell culturing

Juliette van den Dolder  
CEO  
Hefziba ten Brink  
COO



# Future vision

## Diagnostics



## Transplants






# From **lab** to the **clinic** is blocked; **Noviogel** unblocks the path


Animal origin



Synthetic




**Matrigel**



2D and 3D  
research

**Noviogel**



Large Batch  
to batch variations





# Noviogel: Better than other synthetic gels

Elastic like natural matrixes



Thermoreversible






# Competitive landscape

	Matrigel	Synthetic gels	Noviogel
Constant composition	--	+	++
Post culturing processing	-	-	++
Ability to scale up	-	+	++
Biocompatibility	--	+/-	++
Control biomechanical properties	-	-	++
Cell growth	++	+/-	++
Organoids growth	+	+/-	+





# Pig Jejunum Organoids







# Pancreatic tumor organoids



Data showed **increased expression** levels of ACSM3, GCNT3, NT5E, TNS4 and UGDH in organoids cultured **in Noviolgel**. This may suggest that the irregularly shaped organoids grown in Noviolgel better reflect the original tumor phenotype.




## 23% Annual growth rate to over €2B in 2020

### Matrigel:

- 70% market share (> 95% scientific publications)
- Worldwide revenue €200M
- Synthetic market growing

### 3D cell culture market:

- €467M in 2016
- an annual growth rate of 23%
- > €2B in 2020







# Product Development Plan

2018

2020

2025

## Research Use Only



- Estim. Revenue €3M in 2021
- Seed funding needed for market introduction

## Companion Diagnostics



- Ongoing projects within Noviocyte for tissue models, for instance for Organ on a chip
- Market size €6.5B in 2022, CAGR 20%

## Regenerative medicine







## Take home message

### Contact details:

Juliette van den Dolder, PhD

 +31 (0)6 46155064

 j.vandendolder@noviocyte.com

 Kloosterstraat 9  
5349 AB Oss  
The Netherlands

- Noviogel is an innovative solution for 3D cell culture and future clinical applications
- Innovative product in a fast growing market that are unmatched by our competitors



Noviocyte is partner in an EU funded Eurostars project called HYDRO!



Noviocyte has received Early Phase Financing (VFF) from RVO



Noviocyte is partner in a FETproactive project called MechanoControl.